Properties and therapuetic use of atypical antipsychotics: A review;Atypische neuroleptika: Neue wege in der pharmakotherapie schizophrener störungen

Wiener Klinische Wochenschrift

Volumn 112, Issue 24, 2000, Pages 1031-1038

  Hilger, E ^a   Kasper, S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atypical antipsychotics; Extrapyramidal side effects; Negative symptoms; Pharmacotherapy; Schizophrenia

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; AMISULPRIDE; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HISTAMINE H1 RECEPTOR; MUSCARINIC M1 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SERTINDOLE; SIGMA OPIATE RECEPTOR; ZIPRASIDONE;

AGRANULOCYTOSIS; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN TISSUE; MOTOR DYSFUNCTION; PSYCHOSIS; RECEPTOR BLOCKING; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA;

AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; CONTROLLED CLINICAL TRIALS; DIBENZOTHIAZEPINES; DIBENZOTHIEPINS; HALOPERIDOL; HUMANS; IMIDAZOLES; INDOLES; MULTICENTER STUDIES; PIPERAZINES; PIRENZEPINE; PLACEBOS; RISPERIDONE; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; SULPIRIDE; THIAZOLES;

EID: 0034704052     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. The use of epidemiology for risk factors research in schizophrenia: An overview and methodological critique
2. A heuristic vulnerability-stress model of schizophrenic episodes
3. Traitement des etats d'exitation ed d'agitation par une methode medicamenteuse derivees de l'hibernotherapie
4. Psychopharmacological implications of dopamine and dopamine antagonists: A crtitical evaluation of current evidence
5. The significance of dopamine receptor blockade for the mechanism of action of neurologic drugs
6. Clozapine, single photon emission tomography and the D2-receptor blockade hypothesis of schizophrenia
7. Understanding the relationship between extrapyramidal side-effects and tardive dyskinesia
8. Differential developement of therapeutic drugs for psychosis
9. Maintenance pharmacology in schizophrenia
10. IBZM-SPECT imaging of dopamine D2 receptors with typical and atypical antipsychotics
11. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs
12. Clozapine. A review of its properties and therapeutic use in schizophrenia
13. The emerging role of clozapine in the treatment of movement disorders
14. Deficit and nondeficit forms of schizophrenia: The concept
15. The positive and negative syndrome scale (PANNS) for schizophrenia
16. Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacological treatment: A review
17. Novel antipsychotics and negative symptoms
18. Clozapine and risperidone: Refining and extending their use
19. Risperidone in the treatment of schizophrenia
20. Risperidone in the treatment of patients with chronic schizophrenia: A multinational, multicentre, double-blind, parallel-group study versus haloperidol
21. Risperidone: Review and assessment of its role in the treatment of schizophrenia
22. Atypical drug therapy for treatment-resistant schizophrenia
23. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
24. Comments on "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders." by Tran and associates
25. A structured trial for the treatment of agitation in dementia
26. Risperidone: Treatment response in adult and geriatic patients
27. Comparison of Risperidone and placebo for psychosis and behavioural disturbances associated with dementia: A randomized, double-dlind trial
28. The behavioural pharmacology of olanzapine, a novel "atypical" antipsychotic
29. The pharmacology of olanzapine and other new antipsychotic agents
30. The Olanzapine HGAD Study Group: Olanzapine versus plazebo and haloperidol
31. Risperidone and olanzapine: Optimal dosing for efficacy and tolerability in patients with schizophrenia
32. Effects of seroquel, clozapine and other putative atypical agents in primate models of EPS
33. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia
34. In vivo 1231 IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol
35. Weight gain induced by olanzapine
36. IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol
37. Multiple fixed doses of seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
38. Seroquel (quetiapine): Preclinical and clinical findings of a new atypical antipsychotic
39. Pre-clinical pharmacology of new atypical antipsychotics in late stage development
40. Neuropharmacology of zotepine, an antimanic drug: A potent blocker of D2 and 5HT2 receptors of human brain
41. Zotepine vs. haloperidol in paranoid schizophrenia: A double-blind trial
42. A comparison of an atypical and typical antipsychotic, zotepine vesus haloperidol in patients with acute exacerbation of schizophrenia: A parallel-group double-blind trial
43. Zotepine in the treatment of schizophrenic patients with prevailing negative symptoms: A double-blind trial vs. haloperidol
44. Delusional depression: Treatment with antidepressants and zotepine or haloperidol
45. Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol-a 123I-IBZM SPECT study
46. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound
47. A review of the benefit: Risk profile of sertindole
48. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia
49. Kardiovaskuläre Nebenwirkungen bei Neuroleptika-Therapie
50. Behavioural pharmacology of CP-88.059: A new antipsychotic with both 5HT2 and D2 antagonist activities
51. Ziprasidone: A novel antipsychotic with unique pharmacology and therapeutic potential
52. Ziprasidone
53. "Atypische" Neuroleptika in der Schizophreniebehandlung
54. Amisulprid new data in the productive and deficit forms of schizophrenia: A review
55. Amisulprid: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia
56. Amisulprid compared with standard neuroleptics in acute exacerbations of schizophrenia
57. Amisulprid versus plazebo in the medium-term treatment of the negative symptoms of schizophrenia
58. Treatment of negative symptoms in schizophrenia with amisulprid
59. Haloperidol and amisulprid cause different side-effects and negative symptoms in healthy volunteers
60. Treatment of schizophrenia: The expert consensus guideline series
61. Good medical practice in antipsychotic pharmacotherapy
62. Themenheft "Schizophrenie"
63. Tolerability of atypical antipsychotics
64. Weight gain: Side effect of atypical neuroleptics?
65. Clozapine and risperidone: Refining and extending their use
66. (Potentielle) Antipsychotika mit neuartigen Wirkmechanismen